CSL Completes Sale of JRH Biosciences

CSL Completes Sale of JRH Biosciences

Melbourne, Australia — 01/03/2005

CSL Limited announced today that it has completed the sale of its JRH Biosciences Division (JRH) to Sigma-Aldrich Corporation for US$370m cash subject to normal closing adjustments.

CSL’s Managing Director, Dr Brian McNamee, said, “JRH is now positioned to move into its next stage of development and we hope that Sigma-Aldrich can build on the strategic value that JRH brings to its cell culture reagent business.”

Dr McNamee added that he wished the people at JRH who had done so much to build the business over the recent past, every success for the future in continuing to grow and develop that business.

Download this release: CSL Completes Sale of JRH Biosciences

For further information, please contact:

Investors
Mark Dehring
Head of Investor Relations
CSL Limited
Telephone: +613 9389 2818
Email:mark.dehring@csl.com.au

Media
Ms Rachel David
Director of Public Affairs
CSL Limited
Mobile: 0401 775 779
or
Hintons
Tim Duncan
Telephone: +61 3 9600 1979
Mobile: 0408 441 122
© 2016 CSL Limited